| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net product revenue | 239,455 | 200,489 | 184,733 | 186,038 |
| Cost of product sold | 59,650 | 38,153 | 31,994 | 42,778 |
| Gross profit | 179,805 | 162,336 | 152,739 | 143,260 |
| Research and development | 54,962 | 50,159 | 34,540 | 25,387 |
| Sales and marketing | 29,549 | 30,073 | 30,711 | 27,576 |
| General and administrative | 29,807 | 33,924 | 31,243 | 28,587 |
| Total operating expenses | 114,318 | 114,156 | 96,494 | 81,550 |
| Operating income | 65,487 | 48,180 | 56,245 | 61,710 |
| Other expense, net | -106 | -193 | -276 | -124 |
| Interest expense | 3,621 | 3,646 | 3,836 | 4,348 |
| Interest income | 5,730 | 5,296 | 5,044 | 4,932 |
| Income before income taxes | 67,490 | 49,637 | 57,177 | 62,170 |
| Income tax expense | 16,625 | 9,861 | 11,617 | 16,077 |
| Net income | 50,865 | 39,776 | 45,560 | 46,093 |
| Unrealized income on investments | 118 | -6 | 179 | 733 |
| Comprehensive income | 50,983 | 39,770 | 45,739 | 46,826 |
| Earnings per share, basic | 0.88 | 0.69 | 0.79 | 0.81 |
| Earnings per share, diluted | 0.87 | 0.68 | 0.78 | 0.79 |
| Weighted average number of shares outstanding, basic | 57,550,902 | 57,469,775 | 57,309,938 | 56,870,234 |
| Weighted average number of shares outstanding, diluted | 58,717,910 | 58,427,134 | 58,524,566 | 58,103,963 |
Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. (HRMY)